Full-Time
Senior Enterprise Implementation Manager
Collate
11-50 employees
AI-driven documentation automation for life sciences
No salary listed
San Francisco, CA, USA
In Person
Fully in-person role; on-site in San Francisco, CA.
 Business & Strategy (2) |
|---|
| , |
- Four or more years of client-facing implementation experience, successfully leading enterprise software or platform deployments, preferably within life sciences, biotech, or other highly regulated industries.
- Proven ability to lead complex, multi-stakeholder projects from kickoff through delivery, with strong skills in planning, scheduling, risk management, and keeping cross-functional teams aligned.
- Meticulous and detail-oriented approach to requirements gathering, solution design, and execution, with the ability to anticipate gaps, catch inconsistencies, and ensure deliverables standards.
- Excellent written and verbal communication skills, with the ability to translate technical and scientific concepts for diverse audiences and to build strong relationships with clients and internal teams.
- Lead Full-Cycle Implementations by driving implementations from kickoff to go-live, including scoping, requirements gathering, configuration, testing, training, and deployment.
- Serve as the primary liaison for clients and stakeholders, understanding complex scientific and regulatory workflows and ensuring their successful lift-off.
- Collaborate cross-functionally with Product, Engineering, and Operations teams to define deliverables, manage scope, address technical challenges, and adapt solutions for regulated environments.
- Develop and manage detailed project plans, maintain schedules, track milestones, manage risks, and escalate issues to ensure punctual, high-quality delivery.
- Capture customer insights to inform product enhancements and contribute to refining internal implementation methodologies, templates, and tools to scale operations efficiently.
- Work experience in pharmaceutical, biotechnology, or medical device industries.
- Prior experience at a startup—able to wear multiple hats, thrive in ambiguity, and build structure in fast-paced, high-growth environments.
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Seed
Total Funding
$30M
Headquarters
San Francisco, California
Founded
2025
Simplify's Take
What believers are saying
- Pfizer's 20% manufacturing throughput gains validate AI documentation automation market demand.[5]
- UCSF ARPA-H funding accelerates open-source drug development, creating IND filing opportunities.[5]
- Moderna's AWS AI integration demonstrates enterprise adoption of automated quality control workflows.[5]
What critics are saying
- Pfizer's proprietary generative AI platform directly competes in manufacturing documentation automation.[5]
- FDA's DARRTS system with AI language models bypasses Collate's regulatory submission tools.[7]
- Open-source models from UCSF and Open Molecular Software Foundation commoditize documentation automation.[5]
What makes Collate unique
- Acquired MantleBio to deepen AI capabilities across entire drug development lifecycle.[1]
- Generative AI automates regulatory submissions, clinical trials, and quality management workflows.[2][3]
- AI Studio and SDK enable custom agents without external infrastructure dependencies.[8]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Company News
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.